What is AMGN stock price today?

AMGN (Amgen Inc) stock is trading at $388.16 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is AMGN stock going up or down today?

AMGN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy AMGN stock now?

The decision to buy AMGN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is AMGN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for AMGN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is AMGN stock overvalued or undervalued?

AMGN currently trades at a P/E ratio of 27.24, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if AMGN is fairly priced.

What is AMGN's P/E ratio?

AMGN has a price-to-earnings (P/E) ratio of 27.24, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is AMGN's market cap?

AMGN (Amgen Inc) has a market capitalization of $209.24 billion, making it a large-cap stock.

What is AMGN's price to book ratio?

AMGN trades at a price-to-book (P/B) ratio of 23.62, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does AMGN pay dividends?

Yes, AMGN pays dividends with a current yield of 0.03%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is AMGN's dividend yield?

AMGN's dividend yield is 0.03%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is AMGN stock a good long-term investment?

AMGN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is AMGN's revenue growth rate?

AMGN has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, AMGN is profitable with a profit margin of 0.2%. This indicates the company generates 0.2 cents of profit for every dollar of revenue.

What are the risks of investing in AMGN?

Key risks for AMGN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does AMGN compare to its competitors?

Compare AMGN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize AMGN's performance and positioning.

What is AMGN's stock price target for 2026?

Our AI model provides price targets for AMGN based on fundamental analysis: Bull case $504.61 (+30%), Base case $446.38 (+15%), Bear case $349.34 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about AMGN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for AMGN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is AMGN's next earnings report?

AMGN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

AMGN - Amgen Inc

NYSE * Health Care * Biotechnology

$388.16

+$8.83 (+2.33%)

About Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

AMGN Key Statistics

Market Cap

$209.24B

P/E Ratio

27.24

P/B Ratio

23.62

EPS

$14.25

Dividend Yield

0.03%

Revenue Growth

+0.1%

Profit Margin

0.2%

Employees

31,500

How AMGN Compares to Peers

AMGN ranks 2nd in revenue growth vs peers

AMGN is the largest company in its peer group by market cap

P/E Rank

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
AMGN(This stock)	$209.24B	27.2	0%	0.2%	-
GILDGilead Sciences	$184.91B	22.0	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$126.19B	32.5	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$82.64B	18.8	0%	0.3%	vs REGN
BIIBBiogen Inc	$28.15B	21.8	-0%	0.1%	vs BIIB
MRNAModerna Inc	$20.93B	N/A	-0%	-1.5%	vs MRNA

Amgen Inc Company Information

Headquarters: California; U.S.A
Website: www.amgen.com
Sector: Health Care
Industry: Biotechnology

AMGN - Amgen Inc

About Amgen Inc

AMGN Key Statistics

How AMGN Compares to Peers

Amgen Inc Company Information

AMGN Lician Score

AMGN Financial Snowflake

Upcoming Events for AMGN